UNSPSC 51102846: Erythromycin/sulfisoxazole

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102846 Erythromycin/sulfisoxazole is a Commodity code that nominally describes a specific antibiotic pharmaceutical combination product, yet the recent state and local opportunities posted under it show limited actual procurement activity aligned with the code's name. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets—neither of which is erythromycin/sulfisoxazole. Seminole County, Florida posted an IFB in June 2026 for procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, also unrelated to the code's nominal scope. State and local health departments and county procurement offices appear to use this code as a general pharmaceutical-products catchall rather than as a precise descriptor of the erythromycin/sulfisoxazole combination; the actual buying spans antibiotics, opioid-antagonist drugs, and ancillary health-support equipment.

Recent activity concentrates in Illinois and Florida, with the Illinois contract representing a high-value multi-year renewal opportunity through cooperative purchasing infrastructure and the Seminole County opportunity reflecting direct county-level procurement with quarterly delivery requirements and FEMA-potential funding compliance obligations. The code shows little relevant recent activity when filtered strictly to erythromycin/sulfisoxazole; the misalignment between the code name and the solicitations posted under it suggests either systematic catalog miscoding by the issuing bodies or that the code has been repurposed to aggregate mixed pharmaceutical acquisitions at the state and local level.